Wall Street Trader schreef op 23 september 2021 17:37:
[...]
GLPG3970 is still on the table as two more trials are to read out even though
it is confirmed the molecule will not be taken forward. Galapagos has stated it is looking for business development opportunities both to fill the hole left in its mid stage pipeline by trial failures and for a market-ready asset ex-US.
There does not appear to be anything new to tell investors on this front at the moment and management have said that finding the right projects could take some time.
Investors will more or less be focussed on the fortunes of the TYK2 until / unless another exciting pipeline asset emerges.
Unfortunately we can't expect much impact on the stock for the rest of the year with no anticipated clinical catalysts in the short term.